IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 38.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,537 shares of the company’s stock after selling 49,476 shares during the period. Jane Street Group LLC owned approximately 0.09% of IDEAYA Biosciences worth $2,520,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Allworth Financial LP boosted its stake in IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after purchasing an additional 800 shares in the last quarter. Covestor Ltd lifted its holdings in shares of IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after buying an additional 922 shares during the period. Quest Partners LLC bought a new position in IDEAYA Biosciences during the second quarter valued at about $41,000. US Bancorp DE grew its holdings in IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after acquiring an additional 689 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in IDEAYA Biosciences by 637.9% in the second quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock worth $68,000 after acquiring an additional 1,684 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IDYA has been the subject of several recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Leerink Partnrs lowered IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Citigroup decreased their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Finally, UBS Group started coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a “buy” rating and a $50.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and an average price target of $53.67.

IDEAYA Biosciences Stock Up 3.3 %

Shares of IDYA stock opened at $25.61 on Monday. The company has a market capitalization of $2.21 billion, a P/E ratio of -10.99 and a beta of 0.79. IDEAYA Biosciences, Inc. has a 12-month low of $24.48 and a 12-month high of $47.74. The firm has a 50-day moving average price of $28.28 and a 200 day moving average price of $33.98.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. As a group, research analysts expect that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.